President Trump bought more than $500,000 in Palantir stock, then publicly praised the federal contractor on Truth Social

Newly released federal ethics filings — periodic transaction reports filed with the U.S. Office of Government Ethics — show that President Donald Trump purchased more than $500,000 in Palantir Technologies stock, accumulating the position over the weeks before he publicly praised the company on Truth Social. Reporting on the disclosures, which surfaced on May 15, 2026, documented the buy-then-tout sequence: the President quietly built the Palantir holding, then used the official public platform to endorse the company, writing "Just ask our enemies." Disclosure ranges cited in subsequent reporting placed the purchase between roughly $500,000 and $630,000; the OGE form reports values only in broad bands.

The recordable abuse is the conflict of interest created when the office-holder uses the visibility of the presidency to boost a company in which he holds a personal financial stake, and whose revenue depends on decisions his administration controls. Palantir is a major federal contractor whose business spans Immigration and Customs Enforcement, the Defense Department, and other agencies the administration directs; the value of its stock is directly sensitive to federal contracting choices the executive branch makes. Using the office's public platform to promote a personally held position in such a company is a discrete self-dealing act — the President stood to benefit personally from the attention and market movement his endorsement produced — layered on top of the standing monetizing-office condition of holding and trading securities in firms his own administration regulates and contracts with.

This entry records the discrete Palantir buy-then-praise sequence as a distinct act. It is separate from the archive's existing record of the aggregate OGE Q1 2026 securities disclosures, which cataloged thousands of transactions across many companies but did not isolate the Palantir purchase or the accompanying public endorsement.